Betta Pharmaceuticals Co
Betta Pharmaceuticals Co
News Article | November 30, 2016
The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Nasopharyngeal Cancer - Pipeline Review, H2 2016 addition with 40 market data tables and 15 figures, spread across 194 pages is available at http://www.reportsnreports.com/reports/703639-nasopharyngeal-cancer-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis abexinostat hydrochloride, Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer, apatinib, ARGX-110, atezolizumab, avelumab, azacitidine, baltaleucel-T, Cellular Immunotherapy for Multiple Sclerosis, Cellular Immunotherapy for Nasopharyngeal Cancer, Cellular Immunotherapy for Oncology, Cellular Immunotherapy for Solid Tumor and Central Nervous System Disorders, Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology, Cellular Immunotherapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma, Epstein-Barr virus vaccine, GSK-2849330 Advenchen Laboratories, Ambrx, arGEN-X BV, Atara Biotherapeutics, AVEO Pharmaceuticals, Betta Pharmaceuticals Co. Ltd., BioDiem Ltd, Biomics Biotechnologies, Celgene Corporation, Cell Medica Limited, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lakewood-Amedex Inc, Merck & Co., Merck KGaA, Molecular Partners AG, Novartis AG, Ono Pharmaceutical Co., Pharmacyclics, Sapvax, Tessa Therapeutics Pte Ltd, Theravectys SA, Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=703639premium report price at US$2000 for a single user PDF license).
News Article | March 2, 2017
BAAR, Switzerland--(BUSINESS WIRE)--Veeam® Software, the innovative provider of solutions that deliver Availability for the Always-On Enterprise™, has expanded its work with Cisco by launching the direct snapshot integration with the Cisco HyperFlex hyperconverged infrastructure (HCI) platform. The integration of Veeam Availability Suite™ with the software-defined networking and computing power of Cisco UCS with the Cisco HyperFlex HX Data Platform is designed to deliver simplicity and enhance efficiency in the modern hybrid cloud era, with Veeam enabling enterprises to reduce backup and recovery times and improve overall operational performance. It is increasingly understood that digital transformation is a critical imperative for enterprises worldwide, irrespective of size or vertical market. Organizations that fail to create value, growth and competitive advantage through new digital offerings and business models risk major consequences including long-term business irrelevance. At the heart of this transformation is the hybrid cloud. IDC forecasts that public IT cloud services revenue will exceed $203.4 billion by 2020, recording a compound annual growth rate (CAGR) of 21.5 percent — almost seven times the rate of overall IT market growth.1 In 2019, public IT cloud services will drive a fifth of the $716 billion aggregate revenue generated by the need for applications, development and deployment tools, infrastructure software, storage, and servers. By 2018, more than half of enterprises' IT infrastructure and software investments will be cloud based (private and public), reaching 60 to 70 percent of IT spend by 2020. Organizations are now reassessing their data centers and embracing a hybrid cloud strategy to meet the challenge of digital transformation. However, maintaining Availability across a hybrid cloud environment is not easy. Which is why today’s news, seeing Veeam operate deeper on the Cisco HyperFlex platform, means businesses can realize not only the increased efficiency and adaptability benefits of Cisco HyperFlex and the computing power of Cisco UCS, but with the integration of Veeam, ensure data remains available 24.7.365 across a multi-cloud environment. “Reducing recovery time for data and applications is paramount for businesses, that’s why today’s announcement is so important for the market,” said Peter McKay, President and Chief Operating Officer, Veeam. "By combining Veeam’s proven Availability solutions with Cisco’s next-generation HyperFlex platform, we can offer customers unmatched data and application availability. This means a business can realize its investment in IT, without the production downtime that stifles its ability to execute and deliver innovative products and services to customers.” Today’s news builds on a successful collaboration between Veeam and Cisco, which began in 2013 with joint solutions based on Cisco UCS server technology and Veeam Availability Suite. Now, as businesses place more critical data and systems online to reap the benefits of digital transformation and utilize data to make better, more informed business decisions, management of that data has become more critical. “Digital transformation is driving explosive growth for Cisco HyperFlex,” said Kaustubh Das, Cisco VP, Product Management, Storage. “Veeam’s data protection solution is now deeply integrated with HyperFlex. This integration helps our customers realize the full potential of a next-gen, hyperconverged infrastructure while allowing for rapid business adaptability, minimizing risk, and decreasing downtime for today’s 24.7.365 operations.” Veeam’s direct integration with Cisco HyperFlex will be available globally in Q2 CY2017. “Enterprises leveraging Cisco Hyperflex got a nice win today with the announcement that Veeam can now do direct snapshots of their infrastructure,” said Dan Thompson, Senior Analyst, 451 Research. “With this new, tighter integration, backups take place lower in stack, freeing up resources and saving precious time in those ever-shrinking windows. This improvement brings with it the possibility of a shorter RPO (recovery point objective), which gives organizations more options within their backup and disaster recovery plans.” “Veeam has enjoyed a long-standing relationship with Cisco, and I am delighted that we are further deepening this relationship with native snapshot integration for Cisco HyperFlex,” said Andy Vandeveld, VP of Alliances at Veeam. “This is another example of Veeam working tightly with best of breed storage and server vendors to deliver greater performance to ensure data availability. Customers have made it clear they want us to partner with the major storage and server vendors to deliver flexible solutions that work and meet their growing demands for Availability. That’s what we’ve done here. Cisco’s HyperFlex offers a significant differentiation for customers looking to scale storage and compute capacity. Now those same customers can benefit from our new direct integration, which delivers market-leading Availability.” “Akris is an international fashion brand with store locations worldwide,” said Thomas Kaeser, CIO, Akris, a leading fashion retailer based in Switzerland. “When we needed a flexible, scalable and secure infrastructure to support our operations we chose, together with our partner Ceruno AG, Cisco HyperFlex and Veeam Availability Suite. Now with deep snapshot integration with HyperFlex, our backups and recoveries will be even faster helping us deliver 24x7 operations.” “Betta Pharmaceuticals Co., Ltd. is undergoing dramatic growth, and the variety of applications used is rapidly increasing. Traditional backup solutions are not scalable and hence are not able to meet the growing needs of the business,” said Chao WANG, IT Manager at Betta Pharmaceuticals Co., Ltd., a high-tech pharmaceutical firm in China. “Veeam’s integration with Cisco HyperFlex solution is highly flexible, scalable and easy to implement. The Veeam snapshot integration makes backups much faster so there is less impact to the production workloads (VMs) when the backups are taken. It only requires the addition of nodes to increase performance and capacity, reducing total cost of ownership (TCO) which meets the demands of our growing business, and showcases the development trend of industries.” “Our goal is to help customers take full advantage of technology and our customers are looking to us to provide them guidance as they navigate the digital transformation,” said Costa Diamandis, Uplinx Advanced Services, a business partner based in Perth, Australia. “Cisco HyperFlex based on UCS servers and Veeam combine to help us fulfill that promise by offering best in class hyperconverged and availability solutions.” Veeam® recognizes the new challenges companies across the globe face in enabling the Always-On Enterprise™, a business that must operate 24.7.365. To address this, Veeam has pioneered a new market of Availability for the Always-On Enterprise™ by helping organizations meet recovery time and point objectives (RTPO™) of less than 15 minutes for all applications and data, through a fundamentally new kind of solution that delivers high-speed recovery, data loss avoidance, verified recoverability, leveraged data and complete visibility. Veeam Availability Suite™, which includes Veeam Backup & Replication™, leverages virtualization, storage, and cloud technologies that enable the modern data center to help organizations save time, mitigate risks, and dramatically reduce capital and operational costs, while always supporting the current and future business goals of Veeam customers. Founded in 2006, Veeam currently has 45,000 ProPartners and more than 230,000 customers worldwide. Veeam's global headquarters are located in Baar, Switzerland, and the company has offices throughout the world. To learn more, visit https://www.veeam.com. Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks.
News Article | November 8, 2016
Bettapharma, an Investment Project of China Everbright Limited, Listed on the ChiNext of Shenzhen Stock Exchange Betta Pharmaceuticals Co., Ltd. ("Bettapharma"), an investment project of China Everbright Limited ("CEL", stock code: 165.HK)'s Medical & Healthcare Fund, was listed on the ChiNext as the first listed innovative pharma company, with stock code: 300558. Bettapharma is a national-level high-tech pharmaceutical company founded by a team of PhD returnees. Bettapharma has established an integrated organization of research and development, manufacturing, sales and marketing with emphasis R&D of innovative drugs and proprietary intellectual property rights. Ever since its establishment in 2003, it has fully committed to R&D and manufacturing of first class national innovative drugs with proprietary intellectual property rights directed at diseases with significant impacts on human health such as malignant tumors, diabetes, cardiovascular and cerebrovascular diseases and so forth. A first class national innovative drug called Icotinib Hydrochloride Tablets (Conmana) fully developed by Bettapharma is the first innovative small molecule-targeted anti-cancer drug with independent intellectual property rights in China. Currently, CEL's Medical & Healthcare Fund has invested in 12 leading companies in healthcare industry at home and abroad, including Hanxiputai, Amcare, Xiuzheng Pharmaceutical, Ambrx and etc. and has successfully exited from Yuwell with profitable return. For more information of Bettapharma, please visit: http://en.bettapharma.com/ About China Everbright Limited China Everbright Limited ("CEL", stock code: 165.HK), established in Hong Kong in 1997, persistently pursues its "Macro Asset Management" strategy with specific focuses on cross-border asset management and investment businesses. CEL manages a portfolio of private equity funds, venture capital funds, sector focus funds, mezzanine funds, hedge funds and principal investment funds, all operated via an international management platform, and provides overseas investors with opportunities to explore and invest in companies with fast growth potential in mainland China. CEL also seeks investment opportunities from overseas and provides diversified financial services for its clients on the mainland. As of 30 June 2016, CEL's total fundraising scale reached over HK$67.8 billion, with a total of 33 funds. China Everbright Limited, a member of China Everbright Group, is the second-largest shareholder of Everbright Securities (stock code: 601788.SH, 6178.HK), a strategic shareholder of China Everbright Bank (stock code: 601818.SH, 6818.HK), the single largest shareholder of the Hong Kong-listed China Aircraft Leasing Group Holdings Limited (stock code: 1848.HK), the largest shareholder of Shanghai Jiabao Industry & Commerce (Group) Co., Ltd (stock code: 600622.SH) and the second-largest shareholder of the Singapore-listed Ying Li International Real Estate Limited (stock code：5DM. SGX). After the launch of "Shanghai-Hong Kong Stock Connect" on 10 April 2014, CEL became one of the first batch of specific stocks listed on The Stock Exchange of Hong Kong that can be directly traded by Mainland investors. By practising its philosophy of "Making Wealth Simple", CEL leverages its own substantial financial strength as well as the position and influence of China Everbright Group and its affiliated companies in the financial industry in China. As a result, the Group has successfully built huge cross-border social and business networks in Hong Kong and the Mainland, and established a reputable image in the market. For more information about CEL, please visit www.everbright165.com. For enquiries, please contact: Golin Jackie Cheung Tel: +852 2501 7901 Email: Max Lau Tel: +852 2501 7905 Email:
Betta Pharmaceuticals Co. | Date: 2014-07-11
Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.
Betta Pharmaceuticals Co. | Date: 2014-06-09
Disclosed is Icotinib phosphate (i.e., the compound of Formula (I)) and polymorph forms thereof, and methods of preparing and using them.
Betta Pharmaceuticals Co. | Date: 2014-06-09
The present invention relates to the polymorphic forms of the compound of Formula I, preparation thereof and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder or a condition, or in the manufacturing of a medicament for the treatment of a disease, a disorder or a condition.
Betta Pharmaceuticals Co. | Date: 2016-08-17
Disclosed are topical preparations for inhibiting tyrosine kinase and preparation methods thereof, and especially topical pharmaceutical compositions for inhibiting tyrosine kinase and preparation methods thereof. The active ingredient of the topical preparations is Icotinib or a pharmaceutically acceptable salt thereof. The preparations are suitable for topical application, with minimal skin irritation, no adverse reactions such as pruritus, burning sensations, tingling, dry skin, erythema and rashes, without parahormone-related side effects such as skin atrophy, pigmentation or hypopigmentation for long-term use, as well as no related dermatological symptoms after drug withdrawal. The preparation methods are easily understood, operable, and controllable, and are suitable for industry mass production.
Betta Pharmaceuticals Co. | Date: 2012-12-28
The present invention relates to the technical field of medicine, and specifically provides methods for preparing Icotinib, Icotinib hydrochloride, and intermediates thereof. These methods avoid the use of phosphorus oxychloride, thereby greatly reducing the emission of pollutants, which is of major benefits to the economy and environment.
Betta Pharmaceuticals Co. | Date: 2014-10-11
Disclosed are topical preparations for inhibiting tyrosine kinase and preparation methods thereof, and especially topical pharmaceutical compositions for inhibiting tyrosine kinase and preparation methods thereof. The active ingredient of the topical preparations is Icotinib or a pharmaceutically acceptable salt thereof. The preparations are suitable for topical application, with minimal skin irritation, no adverse reactions such as pruritus, burning sensations, tingling, dry skin, erythema and rashes, without parahormone-related side effects such as skin atrophy, pigmentation or hypopigmentation for long-term use, as well as no related dermatological symptoms after drug withdrawal. The preparation methods are easily understood, operable, and controllable, and are suitable for industrialization.
Betta Pharmaceuticals Co. | Date: 2014-06-09
Provided are Icotinib maleate (the compound of Formula I) and polymorph forms thereof, and methods of preparing and using them.